中医肿瘤学杂志2024，Vol.6Issue(3)：78-82,5.DOI:10.19811/j.cnki.ISSN2096-6628.2024.05.014
根据"诸湿肿满,皆属于脾"理论探讨宫颈癌术后下肢淋巴水肿辨治思路
Diagnosis and Treatment of Lower Limb Lymphedema after Cervical Cancer Surgery According to the Theory of"All Dampness and Swelling Belonging to Spleen"
摘要
Abstract
Lower limb lymphedema(LLL)is one of the common complications after radical surgery of cervical cancer.According to the theory of"all dampness and swelling belonging to spleen",it is believed that spleen deficiency and dysregulation is the core pathogenesis of lower limb lymphedema.This article recognized the occurrence of lower limb lymphedema from the physiological characteristics of spleen governing the ascendant of usable substances,the physiological function of spleen controlling transportation and transformation,and the physiological connection of spleen governing limbs.It was proposed that replenishing qi to invigorate spleen,warming and tonifying spleen yang,and regulating the qi activity of middle-energizer were the main treatment.Additionally,external treatments such as external application of traditional Chinese medicine,acupuncture and moxibustion therapy,and acupressure and massage and functional exercise methods from the perspective of spleen meridian circulation were combined so as to improve microcirculation of the lower limbs and promote lymphatic reflux.This article provides ideas for expanding the internal and external treatment of lower limb lymphedema after cervical cancer surgery from the perspective of spleen,with a view to guide the clinical application.关键词
宫颈癌术后/下肢淋巴水肿/脾虚失司/内治法/外治法/治脾Key words
cervical cancer after surgery/lower limb lymphedema/spleen deficiency and dysregulation/internal treatment/external treatment/treating spleen分类
中医学引用本文复制引用
石智尧,房致永,任少键,刘津婧,任文俊,王晞星..根据"诸湿肿满,皆属于脾"理论探讨宫颈癌术后下肢淋巴水肿辨治思路[J].中医肿瘤学杂志,2024,6(3):78-82,5.基金项目
第四届国医大师传承工作室 （）
国家中医药传承创新中心的建设(编号:202203) （编号:202203）
第二批国家中医临床研究基地建设单位 （）
山西省中医临床医学研究中心(培育) （培育）
山西省卫健委山西省医学科技创新团队项目(编号:2020TD04) （编号:2020TD04）
山西省卫健委山西省医学重大科技攻关专项(编号:2022XM10). （编号:2022XM10）
